ROS1 and non-small cell lung carcinoma: For treatment with EGFR inhibitors, METamp has been established as a mechanism of acquired resistance, and evidence is accumulating that this could also occur in NSCLC with targeted therapies related to ALK-, RET-, and ROS1-rearrangements.